Compare Huntington Bancshares Incorporated (HBAN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Huntington Bancshares (HBAN) trades at $15.10, down 1.95% amid bearish technical signals and recent earnings volatility. The stock shows mixed fundamentals with a P/E of 11.72 and ROE of 9.23%, while revenue grew to $8.13B in 2025. Recent news highlights margin pressures from higher interest rates and a reduced 2027 outlook, though the company maintains shareholder returns through dividends and buybacks.

HBAN presents a cautious near-term outlook with analyst consensus at $19.60 (30% upside potential) but faces headwinds from net interest margin compression. Investment opportunity lies in valuation discount to peers, while risks include prolonged rate pressures and execution challenges in loan growth. The balanced analyst rating (47% Buy, 47% Hold) reflects uncertainty around timing of recovery.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.